A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
University of Nebraska
Takeda
Perspective Therapeutics
Novartis
VM Oncology, LLC
NeoTX Therapeutics Ltd.
HiFiBiO Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Travera Inc
Incyte Corporation
Incyte Corporation
Azienda Ospedaliera di Padova
A2 Biotherapeutics Inc.
Incyte Corporation
Instituto do Cancer do Estado de São Paulo
Turnstone Biologics, Corp.
Sotio Biotech Inc.
Symphogen A/S
Travera Inc
Molecular Templates, Inc.
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Massachusetts General Hospital
Rain Oncology Inc
Xencor, Inc.
Incyte Corporation
AbbVie
MacroGenics
Shionogi Inc.
Incyte Corporation
Incyte Corporation
Centre Hospitalier Universitaire de Nice
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Stanford University
Valerio Therapeutics
Valerio Therapeutics
University of Chicago